Identification of a novel resistance ALK p.(Q1188_L1190del) deletion in a patient with ALK-rearranged non–small-cell lung cancer
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Genetics,Molecular Biology
Reference13 articles.
1. Tumor resistance against ALK targeted therapy – where it comes from and where it goes;Sharma;Cancers,2018
2. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study;Solomon;Lancet Oncol,2018
3. ALK resistance mutations and efficacy of Lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer;Shaw;J Clin Oncol,2019
4. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance;Okada;EBioMedicine,2019
5. Understanding and targeting resistance mechanisms in NSCLC;Rotow;Nat Rev Cancer,2017
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Lorlatinib as a treatment for ALK-positive lung cancer;Future Oncology;2022-08
2. Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL;Cancers;2021-11-29
3. Crizotinib;Reactions Weekly;2021-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3